Herpes zoster in Germany: Quantifying the burden of disease
Open Access
- 16 June 2011
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 11 (1), 173
- https://doi.org/10.1186/1471-2334-11-173
Abstract
Herpes zoster (HZ) is caused by a reactivation of the varicella-zoster-virus (VZV) and mainly affects individuals aged ≥ 50 years. Vaccines have been licensed or are under development that can protect against HZ and its main complication postherpetic neuralgia (PHN). In Germany, the burden of disease caused by HZ is not well known. To support the decision making process related to a potential vaccination recommendation, we estimated annual HZ disease burden in people aged ≥ 50 years in Germany by utilizing various data sources. We assessed for 2007 and 2008 HZ-outpatient incidence (number of cases per 1,000 person-years, PY) by utilizing the Association of Statutory Health Insurance Physicians (ASHIP) database, which contains nationwide routine outpatient data. For the same time period annual number of HZ-inpatients and HZ-associated deaths were identified by using the Federal Health Monitoring System (FHM). PHN-incidence and loss of quality-adjusted life years (QALYs) caused by HZ were calculated by multiplying number of identified HZ-patients with upper and lower limit estimates for proportion of HZ-cases developing PHN and HZ-related QALY, respectively. For the study period we identified an annual average of 306,511 HZ-outpatients aged 50+, resulting in a HZ-incidence of 9.6/1,000 PY. A total 14,249 HZ-associated inpatients and 66 deaths were reported in both years on average. HZ-incidence increased by age from 6.21 in people 50-54 years to 13.19 per 1,000 PY in people aged ≥ 90 years. Females were significantly more frequently affected than males in terms of outpatient HZ-incidence (11.12 vs. 7.8 per 1,000 PY), inpatient HZ-incidence (0.51 vs. 0.38 per 1,000 PY) and mortality (0.29 vs. 0.10 per 100,000 PY). PHN-incidence was estimated to range between 0.43 and 1.33 per 1,000 PY. Based on these figures, there were between 3,065 to 24,094 QALYs lost due to HZ in persons aged ≥ 50 years in Germany per annum. Our study provides important baseline estimates for HZ-related disease burden in Germany. HZ poses a considerable burden on the health care system in Germany both in terms of outpatient and inpatient services. Follow-up assessments of HZ disease burden are needed to monitor the impact of VZV-vaccinations in Germany.Keywords
This publication has 43 references indexed in Scilit:
- Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in EnglandVaccine, 2011
- Herpes zoster: Burden of disease in FranceVaccine, 2010
- Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based studyBMC Infectious Diseases, 2010
- Health burden and costs of obesity and overweight in GermanyThe European Journal of Health Economics, 2010
- Zoster Vaccine (Zostavax®)Drugs & Aging, 2010
- A Double-Blind, Randomized, Controlled, Multicenter Safety and Immunogenicity Study of a Refrigerator-Stable Formulation of ZostavaxClinical and Vaccine Immunology, 2008
- Herpes Zoster and Postherpetic NeuralgiaDrugs & Aging, 2008
- Pain, Medication Use, and Health-Related Quality of Life in Older Persons With Postherpetic Neuralgia: Results From a Population-Based SurveyThe Journal of Pain, 2005
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsNew England Journal of Medicine, 2005
- Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of LifeClinical Infectious Diseases, 2004